Cannapharmarx, Inc.
CannaPharmaRx, Inc. is a U.S.-listed company that has shifted from its earlier corporate history to focus on cannabis cultivation and medical cannabis product sales, primarily through operations in Canada. The company recommissioned a 55,000 square foot indoor facility in Cremona, Alberta, and now produces and sells medical cannabis and craft products. Its recent revenue growth has been driven by expanded product offerings, improved distribution, and new retail partner relationships. The business remains early-stage and capital constrained, with operations still scaling and significant dependence on financing and related-party support.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCultivated cannabis flower and related medical-use products sold into domestic and export channels.
Higher-specification batches marketed at premium pricing based on potency and quality.
Bulk product sales to retail partners and related-party distributors that move inventory into end markets.
Customers
The company sells cannabis products to retail partners and distributors that place product into medical cannabis channels. Its disclosures also show sales to a related-party Israeli buyer, indicating that export or cross-border commercial relationships are part of the current go-to-market model. Pricing varies by market and batch quality, with premium and medium batches sold at different gram prices across Germany, Israel, Canada, and Portugal. Customer demand is tied to product potency, regulatory acceptance, and the company’s ability to maintain consistent supply and distribution access.
Retail partners buy medical cannabis inventory for resale, helping the company expand market penetration and distribution reach.
Distributors in markets such as Israel and Europe buy batches for local medical cannabis channels and market development.
Affiliated buyers have purchased product and appear to support early commercialization and market access.
Customers seeking higher-THC, higher-priced batches buy for quality and potency differentiation.
Strategy
The company’s strategy is to scale its indoor cannabis farm, increase utilization of the Cremona facility, and expand production capacity over the next one to two years. Management is also focused on improving distribution capabilities and adding retail partners to support revenue growth. A further strategic priority is market development outside Canada, including Israel and other international markets where the company has already referenced pricing and sales relationships. Because the company is capital constrained, financing and related-party support are also central to executing the operating plan.
Higher utilization should spread fixed cultivation costs over more output and improve commercial scale.
Broader channel access is needed to convert production into recurring sales and reduce reliance on a small set of buyers.
The company needs external capital to fund operations, working capital, and expansion while it remains cash constrained.
Geography
Operationally, the company is centered in Alberta, Canada, where it runs its indoor cultivation facility and maintains its principal executive office in Calgary. The Cremona facility is the core production asset and is being ramped up in phases, which makes Canada the key operating geography. Commercially, the company references sales and pricing in Germany, Israel, Canada, and Portugal, suggesting an export-oriented or internationally distributed sales footprint. Because the business depends on cannabis licensing and product standards, geography matters both for regulatory access and for the ability to place product into higher-value markets.
Risks
The most immediate risk is going concern and liquidity risk, as the company reports minimal cash, a large working capital deficiency, and dependence on new financing to continue operations. Cannabis cultivation also carries operational risk because yields, potency, and product quality directly affect sellability and pricing, and the company has already recorded significant inventory impairment from market price compression and sub-threshold THC levels. Regulatory risk is material because cannabis production and sales depend on licenses, compliance with changing standards, and market access in each jurisdiction. The business is also exposed to concentration and related-party risk because financing, leases, and some sales involve affiliated parties, which can limit flexibility and create governance concerns.
The company states it lacks adequate working capital and depends on raising additional capital to meet obligations and continue operations.
Exposure: Corporate liquidity and operating continuity
Management recorded large inventory write-downs because market prices fell and some inventory failed potency thresholds or became less marketable.
Exposure: Gross margin and inventory valuation
Cultivation and sales depend on Health Canada and other jurisdiction-specific standards that can change product recoverability and market access.
Exposure: Operations and sales channels
Sales, leases, loans, and security arrangements involve affiliates and insiders, increasing dependence on non-arm's-length support.
Accounting
Judgemental itemsLarge write-downs were recorded due to market price compression, aging inventory, and THC potency below target thresholds.
Impact: Directly reduces gross margin and can signal product quality or demand issues
Revenue is tied to shipment and acceptance of product sales, making quarterly results sensitive to timing and customer orders.
Impact: Creates volatility in reported revenue and comparability across quarters
Facility leases and royalty agreements with insiders/affiliates affect operating costs and may include default or security provisions.
Impact: Can materially affect cost of goods sold, liabilities, and financing disclosures
Management explicitly discloses material uncertainty about continuing operations, which is central to statement interpretation.
Impact: Affects investor assessment of asset recoverability and financing assumptions
Similar listed companies
Publicly listed companies with a comparable business focus.
IM Cannabis Corp.
IMCC · Medicinal Chemicals & Botanical Products
Cannaisseur Group Inc.
TCRG · Medicinal Chemicals & Botanical Products
Target Group Inc.
CBDY · Medicinal Chemicals & Botanical Products
CordovaCann Corp.
LVRLF · Services-Amusement & Recreation Services
Cannabis Bioscience International Holdings, Inc.
CBIH · Services-Commercial Physical & Biological Research
Hydrofarm Holdings Group, Inc
HYFM · Wholesale-Miscellaneous Nondurable Goods
Last updated: 11/08/2026